15% OFF $200+· CodeSTOCKUP15
Ends November 30Shop now
Lot certificates published
Plain, secure packaging
Purely Peptides
Research Catalog
Catalog/Retatrutide
Retatrutide
#1024
Lyophilized Peptide

Retatrutide 30mg

Retatrutide (LY3437943) is a peptide agonist of the GIP, GLP-1 and glucagon receptors. Structural and receptor-mutagenesis research examines how the same peptide engages all three receptors. This listing contains 30mg of lyophilized material. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.

Strength

15mg$99.9920mg$109.9930mg$129.9940mg$169.99

Select Option

Single (30mg)$129.99

2+ save 5% · 5+ save 10% · 10+ save 20%

Quantity

1
= $129.99
Buy now
  • Free Priority shipping on US orders over $100
  • Ships same day on orders before 2 PM MST
  • Plain, secure packaging
  • Reported measurements · lot RET-20260811-01Bioviridian Inc. · COA7920: purity 99.82%; content 30.88 mg.Krause Analytical LLC · sample ksytstq · Lab #214171: purity 99.3%; content 28.7 mg.Krause Analytical LLC · sample xbhwgh9 · Lab #214170: purity >99.9%; content 28.0 mg.
  • Stock-solution arithmetic — Retatrutide concentration calculator

Batch Tracking

Batch #

RET-20260811-01

Tested

2026-08-23

Purity

Bioviridian Inc. · COA7920: purity 99.82%; content 30.88 mg.Krause Analytical LLC · sample ksytstq · Lab #214171: purity 99.3%; content 28.7 mg.Krause Analytical LLC · sample xbhwgh9 · Lab #214170: purity >99.9%; content 28.0 mg.

Method

RP-HPLC (214 nm)

View Certificate of Analysis
Telegram - @purely_peptides orders@purelypeptides.org

Mechanism of Action

Retatrutide is a triple agonist at GLP-1R, GIPR and the glucagon receptor (GCGR). Li et al. (2024) determined cryo-EM structures of retatrutide bound to each receptor in complex with Gs and examined receptor mutations using cAMP signaling assays. The study identifies shared and receptor-specific peptide contacts in these experimental systems.

Properties

CAS Number

2381089-83-2

Half-Life

Not established

Storage

Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.

Shipping & Delivery

  • Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
  • US shipping from $5. Free Priority on orders $100+ (before discounts).
  • Plain, unmarked packaging — no branding or product names on the outside.
  • Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Full shipping details

Quality & Testing

  • Independently tested by Bioviridian Inc. — identity by LC-MS/MS, purity by RP-HPLC (214 nm).
  • Reported measurements on lot RET-20260811-01:Bioviridian Inc. · COA7920: purity 99.82%; content 30.88 mg.Krause Analytical LLC · sample ksytstq · Lab #214171: purity 99.3%; content 28.7 mg.Krause Analytical LLC · sample xbhwgh9 · Lab #214170: purity >99.9%; content 28.0 mg.
  • USA-based; dispatched from Phoenix, Arizona.
  • Supplied strictly for in-vitro laboratory research — not for human use.

Additional laboratory results (2)

Krause Analytical LLC · sample ksytstq · Lab #214171

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code ksytstq. We list this result under lot RET-20260811-01.

Chromatographic purity
99.3%
Method: HPLC-UV/MS
Measured content
28.7 mg
Method: HPLC-UV-MS
Identity (mass spectral match)
ID Confirmed
Method: HPLC-UV-MS
Label claim
30 mg
% of label, as printed
95.6
COC#
145871
Received
2026-09-18
Analyzed
2026-09-25
Report issued
2026-10-01
Laboratory address
8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director
Mark C. Krause
PDF SHA-256
af3a211da9ed8c4006d539d0a59c80b37fd79bbecd45ae2020083ad70869055c
Original full certificate (PDF) · ksytstq

Krause Analytical LLC · sample xbhwgh9 · Lab #214170

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code xbhwgh9. We list this result under lot RET-20260811-01.

Chromatographic purity
>99.9%
Method: HPLC-UV/MS
Measured content
28.0 mg
Method: HPLC-UV-MS
Identity (mass spectral match)
ID Confirmed
Method: HPLC-UV-MS
Label claim
30 mg
% of label, as printed
93.3
COC#
145871
Received
2026-09-18
Analyzed
2026-09-25
Report issued
2026-10-01
Laboratory address
8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director
Mark C. Krause
PDF SHA-256
30dddd9387a1b8b06b344b260b345b5a1f1180741773a332d849fee6725c2713
Original full certificate (PDF) · xbhwgh9
Lot RET-20260811-01 · certificatesBioviridian Inc. · COA7920: purity 99.82%; content 30.88 mg.Krause Analytical LLC · sample ksytstq · Lab #214171: purity 99.3%; content 28.7 mg.Krause Analytical LLC · sample xbhwgh9 · Lab #214170: purity >99.9%; content 28.0 mg.

Research Applications

1Triple-receptor complex structural analysis
2Receptor-mutagenesis and cAMP signaling assays
3Comparative incretin and glucagon receptor pharmacology

References & Citations

(1)
1

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

Li W, Zhou Q, Cong Z, et al.

Cell Discov (2024)PMID: 39019866 DOI

Other strengths

Retatrutide 15mg

#1004

$99.99

Retatrutide 20mg

#1062

$109.99

Retatrutide 40mg

#1039

$169.99

Related Products

Retatrutide + Cagrilintide

5mg / 5mg

$124.99

Research Use Only

This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.

Research reference

A published identity, mechanism, and bibliography record corresponds to this catalog entry.

Research reference: Retatrutide

More references from the Research Library (9)

Further papers cited in the Library's Retatrutide record, each checked against PubMed. They describe the compound in research settings and are not statements about this product. See the full record for its identity, structure and complete bibliography.

  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

    Coskun T, Urva S, Roell WC, et al.

    Cell metabolism (2022)In vitro · Animal · Human participants (interventional)PMID 35985340
  2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

    Jastreboff AM, Kaplan LM, Frías JP, et al.

    The New England journal of medicine (2023)Human participants (interventional)PMID 37366315
  3. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

    Rosenstock J, Frias J, Jastreboff AM, et al.

    Lancet (London, England) (2023)Human participants (interventional)PMID 37385280
  4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

    Sanyal AJ, Kaplan LM, Frias JP, et al.

    Nature medicine (2024)Human participants (interventional)PMID 38858523
  5. Pharmacology, physiology, and mechanisms of incretin hormone action.

    Campbell JE, Drucker DJ

    Cell metabolism (2013)Review articlePMID 23684623
  6. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.

    Zhang Y, Sun B, Feng D, et al.

    Nature (2017)In vitroPMID 28538729
  7. Structural basis for ligand recognition of incretin receptors.

    Underwood CR, Parthier C, Reedtz-Runge S

    Vitamins and hormones (2010)Review articlePMID 21094903
  8. Structure of the full-length glucagon class B G-protein-coupled receptor.

    Zhang H, Qiao A, Yang D, et al.

    Nature (2017)In vitroPMID 28514451
  9. Structure of the glucagon receptor in complex with a glucagon analogue.

    Zhang H, Qiao A, Yang L, et al.

    Nature (2018)In vitroPMID 29300013